ILLUMINA INC (ILMN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ILMN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ILMN | Independent Chair | 53 | ["Partner at New Enterprise Associates","senior fellow at AEI","Former FDA Commissioner","Director at Pfizer","United Health","Tempus AI","Extensive policy expertise","Experience as FDA Commissioner (2017-2019)","Senior fellow at AEI","Various roles in public and private sectors","Venture Partner at New Enterprise Associates (2007 – 2017)","FDA Deputy Commissioner for Medical and Scientific Affairs (2005 – 2007)","Senior Advisor for Medical Technology to the FDA Commissioner (2003 – 2004)","Columnist for Wall Street Journal","Contributor to CNBC and CBS Face the Nation","Elected Member of the National Academy of Medicine","Director at United Health","Director at Tempus AI"] | ["Nominating/Corporate Governance"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| TEM | Director | 53 | ["Member of board of directors since October 2019","Partner on NEA’s healthcare investment team since April 2019","Resident Fellow at American Enterprise Institute since April 2021","23rd Commissioner of the U.S. Food and Drug Administration from May 2017 to April 2019","Venture Partner at NEA from January 2007 to May 2017","Senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004","Contributor to CNBC and CBS News program Face the Nation","Executive committee member of Mount Sinai Health System’s board of directors","Co-chair of board’s education committee","Board member of Wesleyan University","Holds a B.A. from Wesleyan University and an M.D. from Mount Sinai School of Medicine","Extensive experience as a medical policy expert and public health advocate"] | ["Nominating and Corporate Governance Committee"] | 2026 |
| UNH | Former Commissioner of the Food and Drug Administration; Director | 53 | ["Extensive clinical, regulatory and health care expertise","23rd Commissioner of the U.S. Food and Drug Administration","Current Senior Fellow at the American Enterprise Institute","Venture capital experience at New Enterprise Associates","Understanding of national health care policy, patient care and complex regulatory environments"] | ["Health and Clinical Practice Policies","Public Responsibility","Health and Clinical Practice Policies Committee","Public Responsibility Committee"] | 2026 |
| PFE | Director; Chair; Committee Member | 51 | ["Government & Public Policy","Medicine & Science","Healthcare & Pharma"] | ["Chair","Regulatory and Compliance","Science and Technology","Regulatory and Compliance Committee","Science and Technology Committee"] | 2024 |
Biography sourced from the proxy statement filing.
Independent Chair Profile Director since 2020 FDA Commissioner (2017 2019) Age: 53 Board Committees Nominating/Corporate Governance Education B.A. in Economics from Wesleyan University M.D. from Mount Sinai School of Medicine of New York University Relevant Expertise Dr. Gottlieb s extensive policy expertise, including his experience as FDA Commissioner from 2017-2019, contributes to the Board s deeper understanding of the risks and opportunities associated with offering FDA-regulated products especially as our growth continues to become more dependent on clinically approved products. Career Highlights Partner, New Enterprise Associates and senior fellow at AEI, a public policy think tank (since 2019) 23rd Commissioner, FDA (2017 2019) Various roles in the public and private sectors including serving as Venture Partner at New Enterprise Associates (2007 2017) FDA Deputy Commissioner for Medical and Scientific Affairs (2005 2007) Senior Advisor for Medical Technology to the FDA Commissioner (2003 2004) Public Board Service Pfizer, Inc. (since 2019) Tempus AI, Inc. (since 2019) UnitedHealth Group (since 2025) Non-Public Board Service Mount Sinai Medical System, Inc. (since 2023) Commanche Biopharma (since 2023) National Resilience, Inc. (since 2020) Xaira Therapeutics (since 2024) Aetion, Inc (2019 2025) Of Note Columnist, Wall Street Journal Contributor to CNBC and CBS Face the Nation Elected Member of the National Academy of Medicine